-
gadolinium(3+) ion 2-[4,7-bis(carboxylatomethyl)-10-(1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecan-1-yl]acetate
-
ChemBase ID:
4441
-
Molecular Formular:
C18H31GdN4O9
-
Molecular Mass:
604.71014
-
Monoisotopic Mass:
605.13320659
-
SMILES and InChIs
SMILES:
C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])C(CO)C(CO)O)CC(=O)[O-].[Gd+3]
Canonical SMILES:
OCC(C(N1CCN(CCN(CCN(CC1)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])CO)O.[Gd+3]
InChI:
InChI=1S/C18H34N4O9.Gd/c23-12-14(15(25)13-24)22-7-5-20(10-17(28)29)3-1-19(9-16(26)27)2-4-21(6-8-22)11-18(30)31;/h14-15,23-25H,1-13H2,(H,26,27)(H,28,29)(H,30,31);/q;+3/p-3
InChIKey:
ZPDFIIGFYAHNSK-UHFFFAOYSA-K
-
Cite this record
CBID:4441 http://www.chembase.cn/molecule-4441.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
gadolinium(3+) ion 2-[4,7-bis(carboxylatomethyl)-10-(1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecan-1-yl]acetate
|
|
|
IUPAC Traditional name
|
gadolinium(3+) 2-[4,7-bis(carboxylatomethyl)-10-(1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecan-1-yl]acetate
|
|
|
Brand Name
|
|
Synonyms
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
Data Source
|
Data ID
|
Price
|
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
1.5443879
|
H Acceptors
|
13
|
H Donor
|
3
|
LogD (pH = 5.5)
|
-10.374291
|
LogD (pH = 7.4)
|
-12.051273
|
Log P
|
-9.238706
|
Molar Refractivity
|
141.0588 cm3
|
Polarizability
|
42.573895 Å3
|
Polar Surface Area
|
194.04 Å2
|
Rotatable Bonds
|
10
|
Lipinski's Rule of Five
|
false
|
Log P
|
-0.47
|
LOG S
|
-1.31
|
Solubility (Water)
|
3.52e+01 g/l
|
PROPERTIES
PROPERTIES
Bioassay(PubChem)
DETAILS
DETAILS
DrugBank
DrugBank -
DB06703
|
Item |
Information |
Drug Groups
|
approved |
Description
|
Gadobutrol is a contrast agent used in magnetic resonance imaging (MRI). |
Indication |
For diagnostic use only. Indicated for adults and children, age 2 and over, for contrast enhancement during cranial and spinal MRI and for contrast-enhanced magnetic resonance angiography (CE-MRA). Gadobutrol is particularly suited for where the exclusion or demonstration of additional pathology may influence the choice of therapy or patient management, for detection of very small lesions and for visualization of tumors that do not readily take up contrast media. May also be suitable for perfusion studies for the diagnosis of stroke, detection of focal cerebral ischemia and tumor perfusion. |
External Links |
|
|
PATENTS
PATENTS
PubChem Patent
Google Patent